STOCK TITAN

IRIDEX (IRIX) SEC Filings, Aug-Sep 2025

IRIX NASDAQ

Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.

Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.

Rhea-AI Summary

Iridex Corp (IRIX) insider purchase: Chief Financial Officer Romeo R. Dizon purchased 1,500 shares of Iridex common stock on 09/09/2025 at a price of $1.37 per share. Following the transaction, the reporting person beneficially owns 57,750 shares. The Form 4 was filed indicating the transaction code "P" and was signed by an attorney-in-fact on 09/10/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
insider
-
Rhea-AI Summary

IRIDEX Corporation reports that it has regained compliance with Nasdaq’s continued listing standards. Based on its Form 10-Q for the quarter ended June 28, 2025, the company now meets the Nasdaq Listing Rule 5550(b)(1) minimum stockholders’ equity requirement of $2,500,000 for the Nasdaq Capital Market.

Nasdaq has informed IRIDEX that the prior non-compliance matter is closed, removing the earlier listing deficiency. The company also issued a press release on September 9, 2025 to highlight its renewed compliance with the stockholders’ equity requirement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
current report
-
Rhea-AI Summary

Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported an insider purchase of common stock. On 09/08/2025 he acquired 500 shares at $1.40 per share, increasing his reported beneficial ownership to 56,250 shares. The Form 4 was signed on 09/09/2025 by an attorney-in-fact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
insider
Rhea-AI Summary

Iridex Corp (IRIX) insider purchase reported: Chief Financial Officer Romeo R. Dizon acquired 1,000 shares of Iridex common stock on 09/05/2025 at $1.35 per share, increasing his beneficial ownership to 55,750 shares. The Form 4 was signed by an attorney-in-fact on 09/08/2025. No derivative transactions or additional details were reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
insider
-
Rhea-AI Summary

Iridex Corp (IRIX) Form 4: Romeo R. Dizon, identified as the Chief Financial Officer, reported three transactions on 09/04/2025. The filing shows acquisitions of 404, 96, and 625 common shares at prices of $1.32, $1.345, and $1.39 respectively. After those transactions the filing lists beneficial ownership totals of 54,029, 54,125, and 54,750 shares. The form was signed by an attorney-in-fact on 09/05/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
insider
-
Rhea-AI Summary

Iridex Corp (IRIX) insider filing shows Chief Financial Officer Romeo R. Dizon, via attorney-in-fact, purchased 625 shares of common stock on 09/03/2025 at $1.36 per share, bringing his beneficial ownership to 53,625 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
insider
Rhea-AI Summary

Romeo R. Dizon, Chief Financial Officer of Iridex Corp (IRIX), reported a purchase of 625 shares of the company's common stock on 09/02/2025 at a price of $1.34 per share, increasing his beneficial ownership to 53,000 shares. The Form 4 was signed by an attorney-in-fact on 09/03/2025. The filing documents a routine insider purchase by a named officer and identifies no derivative transactions or additional disclosures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
insider
-
Rhea-AI Summary

Iridex Corp (IRIX) Form 4: The reporting person, Romeo R. Dizon (CFO), made a purchase of 625 shares of Iridex common stock on 08/29/2025 at a price of $1.37 per share. Following the transaction, Mr. Dizon beneficially owned 52,375 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
insider
-
Rhea-AI Summary

Romeo R. Dizon, Chief Financial Officer of Iridex Corp (IRIX), reported multiple open-market purchases totaling 1,005 shares on 08/28/2025. The transactions executed at prices between $1.325 and $1.36 per share increased his direct beneficial ownership from 50,745 shares to 51,750 shares. Individual purchases reported: 50 shares at $1.33, 200 shares at $1.325, 250 shares at $1.35 and 505 shares at $1.36. The Form 4 was signed by an attorney-in-fact on 08/29/2025. No derivative transactions were reported and no additional explanatory text was provided.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
Rhea-AI Summary

Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported purchases of common stock on 08/27/2025. The filing shows three open-market acquisitions totaling 1,000 shares: 500 shares at $1.28, 250 shares at $1.2746, and 250 shares at $1.2964. Each line reports the resulting beneficial ownership rising sequentially to 50,245; 50,495; and 50,745 shares, and ownership is reported as direct. No derivative transactions were reported. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
insider

FAQ

How many IRIDEX (IRIX) SEC filings are available on StockTitan?

StockTitan tracks 98 SEC filings for IRIDEX (IRIX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for IRIDEX (IRIX)?

The most recent SEC filing for IRIDEX (IRIX) was filed on November 17, 2026.